Innovent Announces NMPA Approval of Limertinib, a Third-generation EGFR TKI Collaborated with ASK Pharma, for the First-line Treatment of Lung Cancer

Approval of Limertinib: Innovent Biologics has received approval from China's National Medical Products Administration for limertinib as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations, following positive results from a Phase 3 clinical trial showing significant improvement in progression-free survival compared to gefitinib.

Collaboration and Future Plans: Innovent and ASK Pharm have partnered to commercialize limertinib in Mainland China, with ongoing efforts to enhance its application, including trials combining it with other therapies for NSCLC resistant to existing treatments.